Celebrating 25 years Est 1999-2024
*Across 3 years $2276.64 only $796.82
June 4, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...
$398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target...
May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global...
May 7, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...
May 2, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years...
RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable...
March 26, 2024 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology...
VYVGART® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia...
ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years Abstracts...
$374 million in fourth quarter and $1.2 billion in full year global net product sales sBLA for VYVGART®...
February 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology...
February 22, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology...
Prescription Drug User Fee Act (PDUFA) target action date is June 21, 2024 If approved, VYVGART® Hytrulo...
Availability of VYVGART® and self-administered VYVDURA demonstrates continued commitment to providing more...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.